147460-43-3

Basic information

• Product Name: 2-Bromo-5-fluorothioanisole
• Synonyms: 2-Bromo-5-fluorothioanisole;(2-Bromo-5-fluorophenyl)(methyl)sulfane
• CAS NO: 147460-43-3
• Molecular Formula: C₇H₆BrFS
• Molecular Weight: 221.0899432
• Mol File: 147460-43-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 219.8±30.0 °C(Predicted)
• Appearance: /
• Density: 1.59±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2-Bromo-5-fluorothioanisole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-5-fluorothioanisole(147460-43-3)
• EPA Substance Registry System: 2-Bromo-5-fluorothioanisole(147460-43-3)

Safety Data

• Hazardous Substances Data: 147460-43-3(Hazardous Substances Data)

Usage

General Description

2-Bromo-5-fluorothioanisole is a chemical compound with the molecular formula C7H6BrFOS. It is a derivative of thioanisole, which is commonly used as a precursor in organic synthesis. The presence of bromine and fluorine atoms in the compound makes it useful in pharmaceutical and agrochemical industries for the synthesis of various compounds, including pharmaceutical drugs and crop protection products. 2-Bromo-5-fluorothioanisole is also known for its characteristic odor and is used as a flavoring agent in the food industry. It is a versatile compound that finds application in diverse industries due to its unique chemical properties.

Upstream product

• 55389-14-5 2-bromo-5-fluorobenzene-1-thiol 
• 74-88-4 methyl iodide 
• 147460-42-2 1-[(2-bromo-5-fluorophenyl)sulfanyl]-N,N-dimethylformamide 
• 147460-40-0 1-(2-bromo-5-fluorophenoxy)-N,N-dimethylmethanethioamide 
• 147460-41-1 2-bromo-5-fluorophenol 
• 624-92-0 Dimethyldisulphide 
• 1003-99-2 2-bromo-5-fluoroaniline 

Downstream Products

• 439942-28-6 4-(4-fluoro-2-methylsulfanyl-phenyl)-4-hydroxy-piperidine-1-carboxylic acid benzyl ester 
• 263863-22-5 4-[(S)-2-methylsulfinyl-4-fluorophenyl]piperidine 
• 1027424-26-5 4-[4-Fluoro-2-((S)-methanesulfinyl)-phenyl]-piperidine-1-carboxylic acid benzyl ester 
• 628692-10-4 1-bromo-4-fluoro-2-(methylsulfonyl)benzene 
• 861931-38-6 2-methylsulfanyl-4-fluoro-benzene boronic acid 
• 147460-44-4 2-(4-Fluoro-2-methylthiophenyl)-4-methoxy-pyridine 
• 1352619-97-6 2-(4-fluorophenyl)-N-{4-[2-({4-[(1-methylpiperidin-4-yl)oxy]-2-(methylsulfanyl)phenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl}acetamide 
• 1352621-27-2 4-[4-bromo-3-(methylsulfanyl)phenoxy]-1-methylpiperidine 

Relevant articles and documents

DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

The present invention relates to di(hetero)arylcyclohexane derivatives of the formula (I), in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

Design, synthesis, and SAR of tachykinin antagonists: Modulation of balance in NK1/NK2 receptor antagonist activity

Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.